Difficulty: Medium
Average Score: 67%
Practice
Main contraindications of estrogensÔÇÖ therapy include the following:
Correct answer
D
Rationale
In the context of cardiovascular drugs, the main contraindications of estrogen therapy are crucial to understand for safe and effective patient care. Option D, "All of the above," is the correct answer because estrogens are contraindicated in estrogen-dependent neoplasms like endometrial or breast carcinoma, as they can promote the growth of these cancers. Additionally, estrogens can cause undiagnosed genital bleeding to worsen, making it important to rule out any underlying issues before initiating therapy. Moreover, estrogens are metabolized in the liver, so pre-existing liver disease can lead to impaired drug metabolism and potential toxicity.
Options A, B, and C are incorrect for the following reasons:
- Option A is incorrect because estrogens can exacerbate estrogen-dependent neoplasms rather than being a suitable treatment.
- Option B is incorrect because undiagnosed genital bleeding can be a sign of underlying gynecological issues that need investigation before starting estrogen therapy.
- Option C is incorrect as liver disease can impact the metabolism of estrogens, potentially leading to adverse effects or decreased efficacy.
Understanding these contraindications is vital in pharmacology to ensure safe prescribing practices and to prevent potential harm to patients. It is essential for healthcare providers to be knowledgeable about these contraindications to make informed decisions when managing patients requiring cardiovascular drug therapy involving estrogens.
Options A, B, and C are incorrect for the following reasons:
- Option A is incorrect because estrogens can exacerbate estrogen-dependent neoplasms rather than being a suitable treatment.
- Option B is incorrect because undiagnosed genital bleeding can be a sign of underlying gynecological issues that need investigation before starting estrogen therapy.
- Option C is incorrect as liver disease can impact the metabolism of estrogens, potentially leading to adverse effects or decreased efficacy.
Understanding these contraindications is vital in pharmacology to ensure safe prescribing practices and to prevent potential harm to patients. It is essential for healthcare providers to be knowledgeable about these contraindications to make informed decisions when managing patients requiring cardiovascular drug therapy involving estrogens.